Cargando…

NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib

Therapy of cutaneous T cell lymphoma (CTCL) is complicated by a distinct resistance of the malignant T cells towards apoptosis that can be caused by NRAS mutations in late-stage patients. These mutations correlate with decreased overall survival, but sensitize the respective CTCL cells towards MEK-i...

Descripción completa

Detalles Bibliográficos
Autores principales:	KieΔling, Michael K., Nicolay, Jan P., Schlör, Tabea, Klemke, Claus-Detlev, Süss, Dorothee, Krammer, Peter H., Gülow, Karsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542218/ https://www.ncbi.nlm.nih.gov/pubmed/28537899 http://dx.doi.org/10.18632/oncotarget.17669

Ejemplares similares

Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat
por: Duvic, Madeleine, et al.
Publicado: (2007)

The Ectopic Expression of Meiosis Regulatory Genes in Cutaneous T-Cell Lymphomas (CTCL)
por: Gantchev, Jennifer, et al.
Publicado: (2019)

28665 Cutaneous T-cell lymphoma (CTCL) outcomes during COVID-19
por: Garcia-Saleem, Tiffany J., et al.
Publicado: (2021)

The Skin Microbiome in Cutaneous T-Cell Lymphomas (CTCL)—A Narrative Review
por: Łyko, Magdalena, et al.
Publicado: (2022)

JAK3 Is Expressed in the Nucleus of Malignant T Cells in Cutaneous T Cell Lymphoma (CTCL)
por: Vadivel, Chella Krishna, et al.
Publicado: (2021)

Safety and danger of biologic treatments in psoriasis in context of cutaneous T-cell lymphoma (CTCL)
por: Kołkowski, Karol, et al.
Publicado: (2021)

A study of meiomitosis and novel pathways of genomic instability in cutaneous T-cell lymphomas (CTCL)
por: Tsang, Matthew, et al.
Publicado: (2018)

Environmental and Other Extrinsic Risk Factors Contributing to the Pathogenesis of Cutaneous T Cell Lymphoma (CTCL)
por: Ghazawi, Feras M., et al.
Publicado: (2019)

Cutaneous T-cell lymphoma (CTCL) exacerbation after viral vector COVID-19 vaccination
por: Panou, Evdoxia, et al.
Publicado: (2021)

Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): focus on chlormethine gel
por: Denis, Daphné, et al.
Publicado: (2019)

International Cutaneous Lymphomas Pandemic Section (ICLYPS) analysis of CTCL outcomes during COVID-19
por: Geskin, Larisa J, et al.
Publicado: (2021)

Contemporary Treatment Patterns and Response in Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) across Five European Countries
por: Assaf, Chalid, et al.
Publicado: (2021)

B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL)
por: Petersen, D L, et al.
Publicado: (2014)

Synergistic cytotoxic activity of cannabinoids from cannabis sativa against cutaneous T-cell lymphoma (CTCL) in-vitro and ex-vivo
por: Mazuz, Moran, et al.
Publicado: (2020)

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
por: Lai, You-Liang, et al.
Publicado: (2022)

Sorafenib, a multikinase inhibitor, induces formation of stress granules in hepatocarcinoma cells
por: Adjibade, Pauline, et al.
Publicado: (2015)

Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib
por: Horger, Marius, et al.
Publicado: (2009)

Connecting the dots in cutaneous T cell lymphoma (CTCL): STAT5 regulates malignant T cell proliferation via miR-155
por: Litvinov, Ivan V, et al.
Publicado: (2013)

Mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) epidemiology and treatment pathway in Spain: new insights for an accurate description
por: D’Agostino, Paolo, et al.
Publicado: (2020)

The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing
por: Tesori, Valentina, et al.
Publicado: (2015)

Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study
por: Nicolay, Jan P., et al.
Publicado: (2023)

Simultaneous Inhibition of mTOR-Containing Complex 1 (mTORC1) and MNK Induces Apoptosis of Cutaneous T-Cell Lymphoma (CTCL) Cells
por: Marzec, Michal, et al.
Publicado: (2011)

Mechlorethamine Hydrochloride Gel in the Treatment of Mycosis Fungoides–Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Focus on Patient Selection and Special Considerations
por: Crimp, Caitlin, et al.
Publicado: (2022)

Ectopic expression of a novel CD22 splice-variant regulates survival and proliferation in malignant T cells from cutaneous T cell lymphoma (CTCL) patients
por: Bagdonaite, Ieva, et al.
Publicado: (2015)

Retraction: Simultaneous Inhibition of mTOR-Containing Complex 1 (mTORC1) and MNK Induces Apoptosis of Cutaneous T-Cell Lymphoma (CTCL) Cells
Publicado: (2020)

Targeting the non‐ATP‐binding pocket of the MAP kinase p38γ mediates a novel mechanism of cytotoxicity in cutaneous T‐cell lymphoma (CTCL)
por: Zhang, Xu Hannah, et al.
Publicado: (2021)

CCR4‐IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T‐cell lymphoma in a mouse CTCL model
por: Wang, Zhaohui, et al.
Publicado: (2023)

Multikinase inhibitors to treat hepatocellular carcinoma failures to sorafenib—time has come for a better approach
por: Alqahtani, Saleh A., et al.
Publicado: (2020)

Brentuximab vedotin: targeting CD30 as standard in CTCL
por: Prince, H. Miles, et al.
Publicado: (2018)

The Anti-Cancer Multikinase Inhibitor Sorafenib Impairs Cardiac Contractility by Reducing Phospholamban Phosphorylation and Sarcoplasmic Calcium Transients
por: Schneider, Christopher, et al.
Publicado: (2018)

Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment
por: Bæk Møller, Nanna, et al.
Publicado: (2019)

Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma()
por: Dietrich, Peter, et al.
Publicado: (2019)

S2k‐Guidelines – Cutaneous lymphomas (ICD10 C82 ‐ C86): Update 2021
por: Dippel, Edgar, et al.
Publicado: (2022)

Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and α-Mangostin
por: Xia, Yun, et al.
Publicado: (2016)

Concomitant Inhibition of FASN and SREBP Provides a Promising Therapy for CTCL
por: Chi, Cheng, et al.
Publicado: (2022)

The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells
por: Schult, Catrin, et al.
Publicado: (2010)

Increased intratumoral fluorothymidine uptake levels following multikinase inhibitor sorafenib treatment in a human renal cell carcinoma xenograft model
por: MURAKAMI, MASAHIRO, et al.
Publicado: (2013)

The PI3K inhibitor pictilisib and the multikinase inhibitors pazopanib and sorafenib have an impact on Rac1 level and migration of medulloblastoma in vitro
por: Schoen, Leonie F., et al.
Publicado: (2022)

Maintenance and Concomitant Therapy Use with Chlormethine Gel Among Patients with Stage IA/IB Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Real-World Evidence Study
por: Querfeld, Christiane, et al.
Publicado: (2022)

Multikinase Inhibitor Treatment in Thyroid Cancer
por: Ancker, Ole Vincent, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_i4ul75o8kgud457eo48nu536o1